Oppenheimer lowered the firm’s price target on Idex Corp. (IEX) to $210 from $212 and keeps an Outperform rating on the shares. The firm recently toured the company’s Rochester, NY Life Sciences Optics Center of Excellence, also meeting with Health & Science Technologies Group Executive Tara Tereso. Oppenheimer came away with a greater appreciation of IH&S differentiation and growth potential, as well as a stronger understanding of Idex’s integrated growth strategy and related value-creation runway.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IEX: